Nivolumab

A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the safety and potential efficacy of neoadjuvant immunotherapy for patients with soft tissue sarcoma.

The FDA approved nivolumab in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, according to a press release.

Subcutaneous nivolumab can reduce burdens on the health care system and patients with pretreated advanced or metastatic clear cell renal cell carcinoma compared with its IV formulation, according to data from a phase 3 CheckMate 67T trial.

Adding sintilimab to chemotherapy improved survival compared with placebo among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, phase 3 study results published in JAMA showed.

In this video, Stephen M. Ansell, MD, PhD, discussed updated study results showing an advantage of nivolumab-chemo over brentuximab vedotin-chemo in both younger and older patients.

MADRID — Remarkable. Highly meaningful. Monumental.

NASHVILLE, Tenn. — Patients with renal cell carcinoma who met eligibility criteria for pivotal phase 3 trials achieved significantly longer survival after combination immunotherapy than trial-ineligible patients, according to study results.

Healio spoke with Hossein Borghaei, DO, MS, about results from the SAPPHIRE trial presented at this year’s ESMO Congress.

MADRID — In a video interview with Healio, Sumanta (Monty) Pal, MD, FASCO, spoke about the STELLAR-304 clinical trial for patients with non-clear cell renal cell carcinoma at ESMO Congress.

Researchers at UT Southwestern Medical Center have introduced a new metric that may be useful in predicting which patients are likely to develop immunotherapy toxicity.